December 13, 2024 Real-world evidence in the cloud: Tutorial on developing an end-to-end data and analytics pipeline using Amazon Web Services resources In the rapidly evolving landscape of healthcare and drug development, the ability to efficiently collect...
November 27, 2024 Voice of the Patient report Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting for ARPKD Patients and their Families Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a rare genetic disease. It occurs in about one in 20,000 births...
November 27, 2024 Autosomal Recessive Polycystic Kidney Disease (ARPKD)Adjunct EL-PFDD Scientific Workshop Report The mission of the Polycystic Kidney Disease Foundation is to fund research, advocate for patients, and ultimately to end PKD..
November 27, 2024 A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies Duchenne muscular dystrophy (DMD), a rare pediatric disease, presents numerous challenges when designing clinical trials...
September 30, 2024 TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction...
October 8, 2024 Flexible approaches to eCOA administration in clinical trials: The site perspective Estelle Haenel, Celeste A. Elash, Katie Garner, Megan Turner, Scottie KernAbstract Electronic Clinical Outcome Assessment (eCOA) C
July 29, 2024 A Modern Curriculum for Training Scientists in Model-Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists C-Path and experienced private sector partners collaborated with global health organizations to create didactic video materials...
June 12, 2024 Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months Digital measures may provide objective, sensitive, real-world measures of disease progression in Parkinson’s disease (PD).
May 28, 2024 Accelerating healthcare innovation: the role of Artificial intelligence and digital health technologies in critical path institute’s public-private partnerships Artificial Intelligence (AI) and Digital Health Technologies (DHTs) are radically transforming drug development. The FDA and EMA..
April 22, 2024 Unlocking the Capabilities of Large Language Models for Accelerating Drug Development Recent breakthroughs in natural language processing (NLP), particularly in large language models (LLMs), offer substantial...
